Table 5. Reported results of stereotactic radiosurgery/stereotactic radiotherapy for paraganglioma (Glomus tumor).
Pts. = patients; Vol. = volume; yr = year; mo = months; GK = Gamma Knife; LINAC = linear accelerator-based system; SRS = stereotactic radiosurgery; SRT = stereotactic radiotherapy; PFS = progression-free survival; FU = follow-up.
| Author, Year | Modality | No. of Pts. | Median Vol. (ml) | Mean Margin Dose (Gy) | Local Control (%) | Survival (%) | Side Effects |
| Hafez et al., 2016 [33] | GK | 22 | 7.3 (mean) (2.8-19.4) | 14.7 SRS (12-16) | 95.5 (5 yr, PFS), 95.5 (7 yr) | 95.5 (5 yr), 95.5 (7 yr) | ND |
| Dobberpuhl et al., 2016 [34] | GK | 12 | up to 4.5 cm in diameter | (12-18) | 100 (FU, 13-96 mo) | 100 (FU, 13-96 mo) | none |
| Winford et al., 2017 [35] | GK | 33 | 5.8 (mean) (0.9-11.4) | 13.2 SRS (11-15) | 95 (5 yr, PFS), 75 (10 yr) | 100 (FU, 5.5-141 mo) | 3.7% |
| Kida et al., (ours), 2000 [4] | GK | 4 | 11.6 (7.5-23.5) | 15.5 SRS (15-16) | 100 (5 yr) | 100 (5 yr) | none |
| Tripathi et al., 2019 [36] | GK SRS/SRT | 10 | 29.9 (mean) (9.95-47.6) | (16-22 SRS, 22.4/2 fx. or 22.9/3 fx.) | 100 (FU, 12-78 mo) | 100 (FU, 12-78 mo) | 1.8% |
| Gigliotti et al., 2018 [37] | LINAC SRS/SRT | 16 | 11.7 (PTV) | (15 SRS, 21/3 fx., or 25-27.5/5 fx.) | 88 (5 yr) | 100 (FU, 55-87 mo) | 6% |